PHASEBIO PHARMACEUTICALS INC (PHAS)
US7172241090 - Common Stock
Overall PHAS gets a fundamental rating of 2 out of 10. We evaluated PHAS against 587 industry peers in the Biotechnology industry. While PHAS seems to be doing ok healthwise, there are quite some concerns on its profitability. PHAS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PHAS had negative earnings in the past year.
PHAS had a negative operating cash flow in the past year.
PHAS had negative earnings in each of the past 5 years.
PHAS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -463.95% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -12738.63% | ||
| PM (TTM) | -12572.13% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PHAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHAS has more shares outstanding
PHAS has a better debt/assets ratio than last year.
2.2 Solvency
PHAS has an Altman-Z score of -42.67. This is a bad value and indicates that PHAS is not financially healthy and even has some risk of bankruptcy.
PHAS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -42.67 |
ROIC/WACCN/A
WACC8.15%
2.3 Liquidity
PHAS has a Current Ratio of 0.47. This is a bad value and indicates that PHAS is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.47 indicates that PHAS may have some problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.47 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
PHAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.61%, which is quite impressive.
PHAS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.09%.
The Revenue has been growing by 152.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.61%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q43.33%
Revenue 1Y (TTM)-92.09%
Revenue growth 3Y152.85%
Revenue growth 5YN/A
Revenue growth Q2Q-97.99%
3.2 Future
The Earnings Per Share is expected to grow by 10.15% on average over the next years. This is quite good.
PHAS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 59.56% yearly.
EPS Next Y59.21%
EPS Next 2Y25.98%
EPS Next 3Y19.21%
EPS Next 5Y10.15%
Revenue Next Year-64.49%
Revenue Next 2Y-51.62%
Revenue Next 3Y19.06%
Revenue Next 5Y59.56%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
PHAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHAS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0 |
4.3 Compensation for Growth
A more expensive valuation may be justified as PHAS's earnings are expected to grow with 19.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.98%
EPS Next 3Y19.21%
5. Dividend
5.1 Amount
PHAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PHASEBIO PHARMACEUTICALS INC
NASDAQ:PHAS (11/2/2022, 8:00:01 PM)
After market: 0.0533 -0.02 (-23.97%)0.0701
-0.02 (-26.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.50M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -463.95% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | -12738.63% | ||
| PM (TTM) | -12572.13% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.47 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)36.61%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y59.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-92.09%
Revenue growth 3Y152.85%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y